Nacalai USA Inc - 92121 San Diego, CA

Business Name: Nacalai USA Inc
Categorized In: Commercial Biotechnical Research
Address: 10225 Barnes Canyon Road # 103, San Diego, CA 92121
Phone Number: (858) 404-0403
Contact Person: Toshi Ono, Vice President
Website Address: nacalaiusa.com
NAICS Code: 5417114
SIC Code: 8731
Business Type: B2B (Business to Business)
Founding Year: 2005
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): Unknown
Share This Business:
Similar Businesses: Proacta Inc - San Diego, CA 92121
Abide Therapeutics - San Diego, CA 92121
Miltenyi Biotec Inc - San Diego, CA 92121
Ignyta - San Diego, CA 92121
Center For Aquaculture Tech - San Diego, CA 92121
Aires Pharmaceuticals Inc - San Diego, CA 92121
Oranox - San Diego, CA 92121
Rd Biosciences Inc - San Diego, CA 92121
Zenobia Therapeutics - San Diego, CA 92121
Arytha Biosciences LLC - San Diego, CA 92121
Abwiz Bio Inc - San Diego, CA 92121
Advantar Laboratories Inc - San Diego, CA 92121
Anaptysbio Inc - San Diego, CA 92121
Nod Pharmaceuticals Inc - San Diego, CA 92121
Kinome Scan - San Diego, CA 92121
Dermatrends Inc - San Diego, CA 92121
One World Lab Inc - San Diego, CA 92121
Motivatrx LLC - San Diego, CA 92121
Mapp Biopharmaceutical Inc - San Diego, CA 92121
Fate Therapeutics Inc - San Diego, CA 92121

Nacalai USA Inc provides professional Commercial Biotechnical Research from its single location at the coordinates 32.899867,-117.19681.

The company offers B2B variables under the SIC code 8731 and NAICS code 5417114, while making an annual revenue of Unknown and hiring a total of 1 to 4 employees.

Founded in 2005, the company can now be visited at 10225 Barnes Canyon Road # 103, San Diego, California 92121 or contacted through representative Toshi Ono, Vice President at (858) 404-0403.

For frequently asked questions and further inquiries about professional Commercial Biotechnical Research, get to know more about Nacalai USA Inc through its company website at nacalaiusa.com. Engage with this business on its social media platforms through on Twitter and on Facebook.